Cannell Peter B & Co. Inc. bought a new position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) in the third quarter, Holdings Channel reports. The firm bought 48,485 shares of the biopharmaceutical company’s stock, valued at approximately $3,739,000.
Several other large investors have also recently modified their holdings of the company. Rockefeller Capital Management L.P. purchased a new position in Agios Pharmaceuticals in the 3rd quarter worth approximately $134,000. Tiverton Asset Management LLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $142,000. Strs Ohio purchased a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $179,000. NewSquare Capital LLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $182,000. Finally, Barrett Asset Management LLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $253,000. Institutional investors and hedge funds own 94.38% of the company’s stock.
In other Agios Pharmaceuticals news, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $69.69, for a total value of $209,070.00. Following the transaction, the insider now directly owns 53,932 shares of the company’s stock, valued at approximately $3,758,521.08. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Steven L. Hoerter sold 2,050 shares of the company’s stock in a transaction that occurred on Friday, August 24th. The shares were sold at an average price of $74.92, for a total value of $153,586.00. Following the completion of the transaction, the insider now directly owns 2,050 shares in the company, valued at $153,586. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,305 shares of company stock worth $1,943,413. 3.02% of the stock is currently owned by corporate insiders.
Shares of AGIO opened at $71.91 on Friday. Agios Pharmaceuticals Inc has a 52-week low of $51.62 and a 52-week high of $99.82.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative net margin of 461.78% and a negative return on equity of 48.51%. The business had revenue of $15.20 million during the quarter, compared to analyst estimates of $22.72 million. During the same period in the previous year, the company earned ($1.59) earnings per share. The business’s revenue for the quarter was up 33.8% on a year-over-year basis. On average, equities analysts anticipate that Agios Pharmaceuticals Inc will post -6.12 EPS for the current year.
Agios Pharmaceuticals Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Further Reading: Swap
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.